Search

Home > Emergency Medical Minute > Podcast # 353: Xofluza
Podcast: Emergency Medical Minute
Episode:

Podcast # 353: Xofluza
Category: Science & Medicine
Duration: 00:03:25
Publish Date: 2018-07-16 11:00:00
Description:

Author: Sam Killian, MD

Educational Pearls:

 

  • Japan recently approved baloxavir marboxil (Xofluza), which may potentially "kill" Flu A/B within 24 hours
  • Recent RCT trial showed superiority over oseltamavir (Tamiflu) in cessation of viral shedding (24 vs 72 hours)
  • Compared to placebo, superior in time to symptom resolution (53.7 vs 80.7  hours)
  • Administered as single dose
  • Yet to be considered for FDA approval

 

References

Portsmouth S, Kawaguchi K, Arai M, Tsuchiya K, Uehara T. Cap-dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza: Results from a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study in Otherwise Healthy Adolescents and Adults with Seasonal Influenza. Open Forum Infectious Diseases. 2017;4(Suppl 1):S734. doi:10.1093/ofid/ofx180.001.

 
Total Play: 0

Users also like

800+ Episodes
Radioresepsj .. 700+     10+
20+ Episodes
Lung Story S .. 70+     10+